Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR Will the Anthrax Vaccine Market Achieve During 2025–2034, and What Does It Indicate?

Over recent years, the anthrax vaccine market has seen a promising growth. Its size is expected to rise from $11.27 billion in 2024 to $11.88 billion in 2025, denoting a compound annual growth rate (CAGR) of 5.4%. This notable expansion in the previous period is mainly due to factors such as anxiety over biological warfare, demand from military sectors, anthrax epidemics, public health readiness, and the implementation of biodefense strategies.

In the coming years, the anthrax vaccine market is anticipated to experience robust growth, expanding to $14.5 billion in 2029 with a compound annual growth rate (CAGR) of 5.1%. This growth prediction for the forecast period can be credited to worldwide security issues, the emergence of new threats, government buying initiatives, and readiness for pandemics. The forecast period is expected to see major trends such as technological innovation, better access in developing countries, emphasis on the development of next-gen vaccines, increased government storage, and cooperative research initiatives.

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Anthrax Vaccine Market?

As the incidence of infectious diseases rises, so too does the anticipated growth of the anthrax vaccine market. These diseases, caused by harmful microorganisms like bacteria, viruses, fungi, or parasites, can spread either directly or indirectly between individuals. Their effects can be anywhere from mild to severe, and in some cases, even lethal, depending on both the pathogen in question and the response of the person’s immune system. The rising occurrence of such diseases is a consequence of numerous factors, including population demographic shifts, urban development, environmental and land-use alterations, and changes in human behaviour. The anthrax vaccine chiefly serves as a protection against anthrax, but ongoing research is investigating its potential wider use in thwarting other infectious diseases, informed by its immunogenic properties and adaptability. For example, it was noted by the US-based non-profit group Council on Foreign Relations in 2023, that up to 75% of newly discovered or emerging infectious diseases (EIDs), and 60% of acknowledged infectious maladies emerged from zoonotic origins. Across the globe, these zoonotic infections lead to an approximate 2.7 million human deaths and 2.5 billion instances of human sickness annually, hence driving the anthrax vaccine market’s growth due to the escalating incidence of diseases.

Request Your Free Anthrax Vaccine Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

Who Are the Key Firms Paving the Way for Growth in the Anthrax Vaccine Market?

Major companies operating in the anthrax vaccine market are:

• Merck & Co. Inc.

• GC Biopharma

• Emergent BioSolutions Inc.

• Indian Immunologicals Limited

• Valneva SE

What Are the Most Influential Trends Currently Shaping the Anthrax Vaccine Market?

Market leaders in the anthrax vaccine industry are concentrating on creating novel products and securing FDA endorsements for their vaccines to assure their safety, effectiveness, and accessibility to those susceptible to anthrax exposure. Acquiring approval from the FDA guarantees that the vaccine has undergone rigorous clinical trial testing and is verified as safe for public consumption, thereby shielding people from any possible harmful effects. As a case in point, Emergent BioSolutions Inc., a biopharmaceutical company based in the US, in July 2023, achieved the approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously referred to as AV7909, from the U.S. Food and Drug Administration (FDA). The endorsement was based on information obtained from a Phase 2 trial which assessed Cyfendus’s compatibility with antibacterial drugs and Phase 3 clinical study that compared its immunogenicity and safety with BioThrax, the former anthrax vaccine. Moreover, the production of safer and more potent adjuvants is crucial to resolve issues related to reactogenicity and increase the overall effectiveness of anthrax vaccines.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Which Key Market Segments Comprise the Anthrax Vaccine Market and Drive Its Revenue Growth?

The anthrax vaccine market covered in this report is segmented –

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine

2) By Application Type: Animal Use, Human Use

3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Subsegments:

1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine

2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

Which Regions Are Essential for the Growth of the Anthrax Vaccine Market?

North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Scope and Reach of the Anthrax Vaccine Market Defined?

The anthrax vaccine is a medical product designed to provide immunity against anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis. The vaccine comprises an inactivated form of the anthrax bacterium or its components, stimulating the body’s immune system to produce antibodies against anthrax toxins. The anthrax vaccine is typically administered through injections, with initial doses followed by booster shots to maintain immunity over time.

Browse Through More Similar Reports By The Business Research Company:

DTP Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Dog Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Inactivated Vaccines Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: